Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics CFO Amello and CMO Louis to leave in reorganization

Neutral Impact 4 of 5 leadership Written later

TScan Therapeutics said its Chief Financial Officer, Jason A. Amello, and Chief Medical Officer, Chrystal Louis, will leave the company as part of a strategic reorganization. Both executives signed separation agreements, with employment ending on the earlier of November 1, 2026 or the date they start other paid work, and their pay and benefits continue until then.

Key points

  • Jason A. Amello (CFO) and Chrystal Louis, M.D., MPH (CMO) are departing under separation agreements dated September 24 and September 25, 2026.
  • Employment ends on the earlier of November 1, 2026 or the executive's start of other employment, consulting or paid board service.
  • Amello may receive a $85,000 lump-sum cash award and Louis a $125,000 award, each payable if a company milestone is achieved before their separation date under the November 2025 retention program.

The filing

CompanyTScan Therapeutics, Inc. (TCRX)
Form8-K, current report
Filed with the SECSep 30, 2026, 5:00 PM ET
Accession number0001193125-26-409199

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.